BPC 157 Dosing (Common Protocols), Oral Subcutaneous, 500 mcg daily, Duration: 6 weeks, Intramuscular Peritendinous, 1 mg daily, Duration: 6 weeks, Note:, Not approved by FDA or Is BPC 157 Banned? Oral vs. Injectable Forms Explained Sample of patents with BPC 157 utilization. Download Scientific Diagram BPC 157 500 mcg Oral Capsules Differences of first pass effect in the liver and intestine contribute to the stereoselective pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats ScienceDirect Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia reperfusion injury following Pringle maneuver, and Budd Chiari syndrome